ライフサイエンスコーパス: oropharyngeal candidiasis

1 tion, and fungal burden in a murine model of oropharyngeal candidiasis.

2 Here we describe a simple mouse model of oropharyngeal candidiasis.

3 1p-N) protects mice against disseminated and oropharyngeal candidiasis.

4 otherapy, and smoking were key predictors of oropharyngeal candidiasis.

5 ard Candida albicans, the causative agent of oropharyngeal candidiasis.

6 m the fluconazole-treated AIDS patients with oropharyngeal candidiasis.

7 method was used to screen for resistance in oropharyngeal candidiasis.

8 virus (HIV)-infected patients with recurrent oropharyngeal candidiasis.

9 cted family of two children with symptomatic oropharyngeal candidiasis and a mother with asymptomatic

10 chanisms are expected for protection against oropharyngeal candidiasis, anti-Candida host defense mec

11 ing identified CD4 cell count and history of oropharyngeal candidiasis as key predictors of salivary

12 xamine the question of strain specificity in oropharyngeal candidiasis associated with human immunode

13 adiation for head and neck cancer to develop oropharyngeal candidiasis due to C. glabrata.

14 , while the comparison group (n = 39) had no oropharyngeal candidiasis during that period.

15 nts with a self-reported history of clinical oropharyngeal candidiasis during the previous 2 years co

16 lbicans that has been recently implicated in oropharyngeal candidiasis in human immunodeficiency viru

17 ogy of which mimics that of pseudomembranous oropharyngeal candidiasis in humans.

18 The pathophysiology of oropharyngeal candidiasis in patients infected with huma

19 andida dubliniensis has been associated with oropharyngeal candidiasis in patients infected with huma

20 w 200 cells/ microl) and positive history of oropharyngeal candidiasis in predicting salivary SLPI le

21 rotein may serve as an indicator of previous oropharyngeal candidiasis infection among immunosuppress

22 Oropharyngeal candidiasis is a frequent cause of morbidi

23 these cytokines in immune protection against oropharyngeal candidiasis is still incompletely understo

24 One important line of defense against oropharyngeal candidiasis is the oral microbiota that pr

25 Oropharyngeal candidiasis (OPC [thrush]) is an opportuni

26 Oropharyngeal candidiasis (OPC) caused by Candida albica

27 The disproportionate increase in oropharyngeal candidiasis (OPC) compared with systemic a

28 ast that has been increasingly implicated in oropharyngeal candidiasis (OPC) in human immunodeficienc

29 -17 receptor (IL-17R) is required to prevent oropharyngeal candidiasis (OPC) in mice and humans.

30 Oropharyngeal candidiasis (OPC) is a common opportunisti

31 Oropharyngeal candidiasis (OPC) is a common oral opportu

32 Oropharyngeal candidiasis (OPC) is among the most common

33 Oropharyngeal candidiasis (OPC) is an opportunistic fung

34 Isolated oropharyngeal candidiasis (OPC) was the most common pres

35 Oropharyngeal candidiasis (OPC), as opposed to vulvovagi

36 Oropharyngeal candidiasis (OPC), caused by Candida albic

37 Oropharyngeal candidiasis (OPC), caused by Candida albic

38 Oropharyngeal candidiasis (OPC), caused by the commensal

39 Oropharyngeal candidiasis (OPC), the most common oral in

40 ungus Candida albicans is the major cause of oropharyngeal candidiasis (OPC).

41 p as an immunogenic protein expressed during oropharyngeal candidiasis (OPC).

42 een described as the infecting organism with oropharyngeal candidiasis (OPC).

43 The commensal fungus Candida albicans causes oropharyngeal candidiasis (OPC; thrush) in settings of i

44 Oropharyngeal candidiasis (OPC; thrush) is an opportunis

45 S patients receiving fluconazole therapy for oropharyngeal candidiasis over a 2-year period were eval

46 and reduced interleukin-17 signalling during oropharyngeal candidiasis, resulting in more severe dise

47 tients with disseminated candidiasis (DC) or oropharyngeal candidiasis than controls.

48 Oropharyngeal candidiasis, typically caused by Candida a

49 By using a mouse model of oropharyngeal candidiasis we found that IL-17A and IL-17

50 eficiency virus (HIV)-infected patients with oropharyngeal candidiasis, we identified three patients

51 At week 7 of his radiation, he developed oropharyngeal candidiasis, which was treated with 200 mg

52 Most episodes of oropharyngeal candidiasis with trailing-endpoint isolate